Brawn Biotech Limited returned to profitability in the financial year ended March 31, 2026, posting a net profit of ₹94.06 lakh compared to a net loss of ₹179.81 lakh in the previous year. The company’s revenue from operations for FY26 stood at ₹1,697.77 lakh. The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, at its meeting held on May 29, 2026.

For the quarter ended March 31, 2026, the company reported a net profit of ₹58.34 lakh. Revenue from operations for the quarter was ₹197.65 lakh. Total comprehensive income for the year increased to ₹97.71 lakh from a negative ₹176.08 lakh in the prior year. The earnings per share (EPS) for the year improved to ₹3.26 from a negative ₹5.87 in the previous year.

Financial Performance

The company’s total expenses for the year amounted to ₹1,743.07 lakh, slightly higher than the total revenue of ₹1,743.18 lakh. Profit from operations before other income and exceptional items was nominal at ₹0.11 lakh for the year. The statutory auditors, M/s Rajiv Udai & Associates, issued an unmodified opinion on the standalone financial results.

Key Financial Metrics

Balance Sheet Highlights

The company’s total assets as of March 31, 2026, were ₹2,085.72 lakh, compared to ₹2,048.90 lakh in the previous year. Total equity increased to ₹433.94 lakh from ₹336.23 lakh. Current assets stood at ₹1,711.99 lakh, while current liabilities were reported at ₹1,517.02 lakh.

The financial results were reviewed by the Audit Committee and are in compliance with the Indian Accounting Standards (Ind AS). The company is primarily engaged in the pharmaceuticals business and has no separate reportable segments as per Ind-AS 108.

Brawn Biotech Ltd has announced that its board of directors will meet on Friday, May 29, 2026. The primary agenda for the meeting is to consider and approve the audited financial results of the company for the quarter and financial year ended March 31, 2026.

Board Meeting Details

The meeting is being convened pursuant to Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board will review the company's performance for the fourth quarter of the fiscal year 2026 and the full fiscal year.

Trading Window Closure

In accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window for dealing in the securities of the company will remain closed. This closure period is effective immediately and will continue until May 31, 2026. The window is scheduled to reopen on June 1, 2026.

The intimation regarding the trading window closure was initially communicated via a letter dated March 30, 2026. This measure ensures compliance with regulatory standards regarding insider trading during the period surrounding financial result announcements.